{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:19:17Z","timestamp":1740122357302,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Frans Van de Werf Fund for Clinical Cardiovascular Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s10741-016-9583-2","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T01:27:57Z","timestamp":1473643677000},"page":"699-701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Should MRAs be at the front row in heart failure? A plea for the early use of mineralocorticoid receptor antagonists in medical therapy for heart failure based on clinical experience"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5368-2223","authenticated-orcid":false,"given":"Ward A.","family":"Heggermont","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Goethals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riet","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Verstreken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"Bartunek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Vanderheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"key":"9583_CR1","unstructured":"Authors\/Task Force M, Document R (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016"},{"key":"9583_CR2","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors\/Task Force M, Document R (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016"},{"issue":"10","key":"9583_CR3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"issue":"1","key":"9583_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Group E-HS (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"1","key":"9583_CR5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"3","key":"9583_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","volume":"91","author":"J Staessen","year":"1981","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91(3):457\u2013465","journal-title":"J Endocrinol"},{"issue":"2","key":"9583_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","volume":"350","author":"S Messaoudi","year":"2012","unstructured":"Messaoudi S, Azibani F, Delcayre C, Jaisser F (2012) Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 350(2):266\u2013272","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"9583_CR8","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM199909023411009","volume":"341","author":"KT Weber","year":"1999","unstructured":"Weber KT (1999) Aldosterone and spironolactone in heart failure. N Engl J Med 341(10):753\u2013755","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"9583_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1006844010371","volume":"189","author":"SH Slight","year":"1998","unstructured":"Slight SH, Chilakamarri VK, Nasr S, Dhalla AK, Ramires FJ, Sun Y, Ganjam VK, Weber KT (1998) Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 189(1\u20132):47\u201354","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"9583_CR10","doi-asserted-by":"crossref","first-page":"12A","DOI":"10.1016\/0002-9149(93)90239-9","volume":"71","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71(3):12A\u201316A","journal-title":"Am J Cardiol"},{"issue":"5","key":"9583_CR11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/FJC.0b013e31822a78c1","volume":"58","author":"PA Deshmukh","year":"2011","unstructured":"Deshmukh PA, Bellary SR, Schwender FT, Kamalov G, Magotra M, de Jongh Curry AL, Sun Y, Weber KT (2011) Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. J Cardiovasc Pharmacol 58(5):487\u2013491","journal-title":"J Cardiovasc Pharmacol"},{"key":"9583_CR12","doi-asserted-by":"crossref","unstructured":"(1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316(23):1429\u20131435","DOI":"10.1056\/NEJM198706043162301"},{"issue":"5","key":"9583_CR13","first-page":"497","volume":"12","author":"B Olechowski","year":"2015","unstructured":"Olechowski B, Sands R, Zachariah D, Andrews NP, Balasubramaniam R, Sopher M, Paisey J, Kalra PR (2015) Is cardiac resynchronisation therapy feasible, safe and beneficial in the very elderly? J Geriatr Cardiol 12(5):497\u2013501","journal-title":"J Geriatr Cardiol"},{"issue":"36","key":"9583_CR14","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/eurheartj\/eht279","volume":"34","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Maggioni AP, Borer JS (2013) Should we revise our approach to \u2018optimal medical therapy\u2019? The case of chronic heart failure. Eur Heart J 34(36):2792\u20132794","journal-title":"Eur Heart J"},{"issue":"5","key":"9583_CR15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pcad.2005.11.002","volume":"48","author":"IF Bukharovich","year":"2006","unstructured":"Bukharovich IF, Kukin M, Cardiac Resynchronization Therapy PiCD (2006) Optimal medical therapy for heart failure. Prog Cardiovasc Dis 48(5):372\u2013385","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-016-9583-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-016-9583-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-016-9583-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T07:09:06Z","timestamp":1568358546000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-016-9583-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["9583"],"URL":"https:\/\/doi.org\/10.1007\/s10741-016-9583-2","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"type":"print","value":"1382-4147"},{"type":"electronic","value":"1573-7322"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}